




The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Therag
NEW YORK--([ BUSINESS WIRE ])--Levi & Korsinsky is investigating the Board of Directors of Theragenics Corporation (aTheragenicsa or the aCompanya) (NYSE: TGX) for possible breaches of fiduciary duty and other violations of state law in connection with the rejection of a merger proposal from Eckert & Ziegler Strahlen- und Medizintechnik AG (aEUZa) (Reuters: EUZ.DE) and its subsidiary IBt Bebig (Reuters: IBTH.BR). Under the terms of the transaction, EUZ would acquire all outstanding shares of Theragenics at a price of $2.20 per share.
Click here to learn more about the investigation: [ http://www.zlk.com/theragenics-tgx.html ], or call: 877-363-5972.
The investigation concerns whether the Board of Theragenics is acting in Theragenics shareholdersa™ best interests by refusing to enter into negotiations with EUZ and rejecting the proposal. In particular, the offer price of $2.20 per share represents more than a 27% premium over the 30-day average closing price of Theragenics stock and over a 47% over the 180-day average closing price.
If you own common stock in Theragenics and wish to obtain additional information, please contact Joseph E. Levi, Esq. either via email at [ jlevi@zlk.com ] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit [ http://www.zlk.com/theragenics-tgx.html ].
Levi & Korsinsky has expertise in prosecuting investor securities litigation and extensive experience in actions involving financial fraud and represents investors throughout the nation, concentrating its practice in securities and shareholder litigation. The attorneys at Levi & Korsinsky have been appointed by numerous courts throughout the country to serve as lead counsel on behalf of shareholders in major litigations involving mergers and acquisitions. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.